Brookline Capital Management Estimates VRCA Q1 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of Verrica Pharmaceuticals in a report released on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.10) per share for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.34) EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The firm had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $1.30 million.

Separately, Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Verrica Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Price Performance

Shares of VRCA opened at $0.60 on Thursday. The business’s fifty day moving average price is $0.68 and its 200 day moving average price is $1.11. Verrica Pharmaceuticals has a 12-month low of $0.54 and a 12-month high of $11.41. The stock has a market capitalization of $27.32 million, a PE ratio of -0.33 and a beta of 1.44.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VRCA. Caligan Partners LP acquired a new position in Verrica Pharmaceuticals during the fourth quarter worth about $5,201,000. Boothbay Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at $1,811,000. Sovran Advisors LLC acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at $267,000. Heights Capital Management Inc. acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at $246,000. Finally, Rhumbline Advisers boosted its position in shares of Verrica Pharmaceuticals by 975.2% in the 4th quarter. Rhumbline Advisers now owns 266,093 shares of the company’s stock valued at $186,000 after purchasing an additional 241,344 shares during the period. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.